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Purpose: The aim of this study was to compare results of National Comprehensive Cancer Network (NCCN) high-risk group 2 with
those of NCCN high-risk group 1 in a clinical CT lung screening program.
Methods: The results of consecutive clinical CT lung screening examinations performed from January 2012 through December 2013
were retrospectively reviewed. All examinations were interpreted by radiologists credentialed in structured CT lung screening reporting,
following the NCCN Clinical Practice Guidelines in Oncology: Lung Cancer Screening (version 1.2012). Positive results required a
solid nodule 4 mm, a ground-glass nodule 5 mm, or a mediastinal or hilar lymph node >1 cm, not stable for >2 years. Signiﬁcant
incidental ﬁndings and ﬁndings suspicious for pulmonary infection were also recorded.
Results: A total of 1,760 examinations were performed (464 in group 2, 1,296 in group 1); no clinical follow-up was available in 432
patients (28%). Positive results, clinically signiﬁcant incidental ﬁndings, and suspected pulmonary infection were present in 25%, 6%,
and 6% in group 2 and 28.2%, 6.2%, and 6.6% in group 1, respectively. Twenty-three cases of lung cancer were diagnosed (6 in group
2, 17 in group 1), for annualized rates of malignancy of 1.8% in group 2 and 1.6% in group 1.
Conclusion: NCCN group 2 results were substantively similar to those for group 1 and closely resemble those reported in the National
Lung Screening Trial. Similar rates of positivity and lung cancer diagnosis in both groups suggest that thousands of additional lives may
be saved each year if screening eligibility is expanded to include this particular high-risk group.
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192Trial (NLST) entry criteria [1-11]. The Preventive Services
Task Force, the National Comprehensive Cancer Network
(NCCN), and others have expanded their screening rec-
ommendations beyond the NLST study population to
include certain younger patients, older patients, and patients
with additional risk factors also considered to be at high risk
for lung cancer [5,7,10]. In October 2011, the NCCN
recommended annual CT lung screening for two groups of
high-risk individuals [7]:
n NCCN high-risk group 1: NLST study population
B 55 to 74 years of age
B 30 pack-year smoking history
B Current or former smokers who quit within past 15
years
n NCCN high-risk group 2
B >50 years of age
B >20 pack-year smoking historyª 2015 American College of Radiology
1546-1440/14/ n http://dx.doi.org/10.1016/j.jacr.2014.08.002
Open access under CC BY-NC-ND license.
Fig 1. Program volume and National Comprehensive Cancer
Network (NCCN) group 2 percentage over time.B Current or former smokers who quit for any length of
time
B At least one additional lung cancer risk factor,
excluding secondhand smoke exposure
- Personal history of smoking-related cancer
- Family history of lung cancer in a ﬁrst-degree
relative
- Chronic lung disease, including emphysema and
pulmonary ﬁbrosis
- Known pulmonary carcinogens
Inclusion of the group 2 population into annual lung
screening has generated controversy because this group was
not formally evaluated in the NLST or other CT lung
screening trials. In January 2012, our institution began of-
fering clinical CT lung screening as a community beneﬁt to
individuals aged 74 years meeting either NCCN group 1
or group 2 high-risk criteria. In this article, we compare the
demographic characteristics and rates of positive ﬁndings,
signiﬁcant incidental ﬁndings, and malignancy between our
group 2 and group 1 populations and the NLST study
results.Table 1. Patient demographics, smoking history, and follow-up
Variable Total NCCN Group 2
Number qualiﬁed 2,079 538
Number screened 1,760 464 (26%)
Average age (y) 64 61
Men 52% 50%
Smoking history (pack-years) 47 40
Current smokers 812 (46%) 167 (36%)
Former smoker duration (y) 10.3 18.5
Clinical follow-up available 1,328 (75%) 331 (71%)
Average follow-up (mo) 12.5 12.1
Note: NA ¼ not applicable; NCCN ¼ National Comprehensive Cancer Netw
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This was a retrospective, single-center study of our experi-
ence with clinical CT lung screening approved by the
institutional review board. We reviewed results for consec-
utive individuals undergoing clinical CT lung screening at
our institution from January 2012 through December 2013.Outline of the Clinical Lung Screening Program
To qualify for screening, individuals had to satisfy the
NCCN high-risk criteria, be asymptomatic, have physician
orders for CT lung screening, be free of lung cancer for 5
years, and have no known metastatic disease. CT scheduling
staff members conducted structured telephone interviews
with screening candidates to assign them into 1 of 3 groups:
group 1 (high risk), group 2 (high risk), or group 3 (mod-
erate or low risk). If screening candidates fulﬁlled the group
1 criteria, other lung cancer risk factors were not assessed.
Those not qualifying for group 1 underwent sequential
assessment of group 2 risk factors. Individuals meeting
group 1 or group 2 high-risk criteria were scheduled to
undergo CT lung screening examinations. If no risk factors
were present or if candidates were outside the age or
required pack-year ranges of group 1 and group 2, they were
assigned to group 3, not enrolled in the screening program,
and referred to discuss the appropriateness of screening with
their primary care providers.Image Acquisition and Interpretation
All CT lung screening examinations were performed on
64-row multidetector CT scanners (LightSpeed VCT and
Discovery VCT [GE Medical Systems, Milwaukee, Wis-
consin]; Somatom Deﬁnition [Siemens AG, Erlangen,
Germany]; iCT [Philips Medical Systems, Andover, Mas-
sachusetts]) at 100 kV and 30 to 100 mA, depending on the
scanner and the availability of iterative reconstruction soft-
ware. Axial images were obtained at 1.25- to 1.5-cm
thickness with 50% overlap and reconstructed with both
soft tissue and lung kernels. Axial maximum-intensityNCCN Group 1 P (Group 2 vs Group 1) NLST
1,541 NA NR
1,296 (74%) NA w26,000
65 <.001 61
53% 0.2 59%
51 <.001 56
645 (50%) <.001 48%
6.7 <.001 NR
997 (77%) NR NA
12.7 NR 78
ork; NLST ¼ National Lung Screening Trial; NR ¼ not reported.
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Fig 2. Group 1 disqualifying factors.projections (16  2.5 mm) and coronal and sagittal mul-
tiplanar reformatted images were reconstructed and used
for interpretation. The average CT dose index was 1.25 
0.2 mGy (range, 1.05e1.56 mGy), and the average dose-
length product was 48.1  9 mGy $ cm (range, 33e61
mGy $ cm).
Image interpretation was performed by radiologists
speciﬁcally trained and credentialed in CT lung screening
using a structured reporting system and the NCCN Clinical
Practice Guidelines in Oncology: Lung Cancer Screening
(version 1.2012) nodule follow-up algorithms [7,12]. Posi-
tive results required the identiﬁcation of a solid, noncalciﬁed
nodule 4 mm, a ground-glass nodule 5 mm, or a
mediastinal or hilar lymph node >1 cm in short axis for
which >2-year stability had not been established. Positive
ﬁndings for which the NCCN guidelines recommended
only repeat low-dose chest CT were categorized as “probably
benign”; any positive ﬁnding requiring advanced imaging
such as PET/CT or an invasive procedure per the NCCN
guidelines was categorized as “suspicious,” and a pulmonary
consultation was recommended [7]. All suspicious cases
were presented at our weekly multidisciplinary thoracic
oncology group meeting. Clinically signiﬁcant incidental
ﬁndings and ﬁndings suspicious for pulmonary infection
were speciﬁcally recorded [12]. All patient information and
examination results were entered into a custom-designed
database (FileMaker Pro version 11; FileMaker Inc, Santa
Clara, California), which served as the data source for this
study.Statistical Analysis
Data analysis included descriptive statistics. All data are re-
ported as mean  SD, range, or percentage as appropriate.
Group comparisons were made using one-way analysis of
variance. For all statistical analysis, the signiﬁcance level for
differences was set at P  .05. All statistical analysis was
performed by using a statistical software platform (SPSS
version 21; SPSS, Inc, Chicago, Illinois).Fig 3. Group 2 qualifying risk factors.RESULTS
Between January 2012 and December 2013, a total of 2,391
individuals were referred for CT lung screening (Fig. 1),
2,079 of whom (88%) fulﬁlled either group 2 (n ¼ 538) or
group 1 (n ¼ 1,541) high-risk criteria (Table 1). Five
hundred thirty-eight of 718 screening candidates (74%) not
meeting group 1 criteria did fulﬁll the group 2 age and
smoking criteria and were found to have at least one addi-
tional qualifying NCCN risk factor (Figs. 2 and 3). Three
hundred twelve of 2,391 (12%) did not meet either high-
risk criteria and were assigned to group 3 and not enrolled
in the screening program.194Four hundred sixty-four of 538 group 2 subjects (86%)
and 1,296 of 1,541 group 1 subjects (84%) underwent
prevalence CT lung screening examinations during the
study interval, for a total of 1,760 examinations (26% in
group 2) (Table 1). Demographics and smoking histories of
group 2 and group 1 patients scanned are presented in
Table 1. Four hundred eighty-one of 1,760 prevalence ex-
aminations (27.3%) had positive ﬁndings: 25.0% in group 2
and 28.2% in group 1. One hundred eight of 1,760 prev-
alence examinations (6.1%) had at least one clinically sig-
niﬁcant incidental ﬁnding: 6.0% in group 2 and 6.2% in
group 1. One hundred fourteen of 1,760 prevalence ex-
aminations (6.5%) had ﬁndings suspicious for pulmonary
infection or inﬂammation: 6.0% in group 2 and 6.6% in
group 1 (Table 2).Journal of the American College of Radiology
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Table 2. Prevalence Exam Results
Result
Total
Screened
(n ¼ 1,760)
NCCN Group 2
(n ¼ 464)
NCCN Group 1
(n ¼ 1,296)
P (Group 2
vs Group 1) NLST (T0)
Total positive 481 27.3% 116 25.0% 365 28.2% 0.1 27.3%
Probably benign 412 23.4% 103 22.2% 309 23.8% NR NR
Suspicious 69 3.9% 13 2.8% 56 4.3% NR NR
Probable infection 114 6.5% 28 6.0% 86 6.6% 0.8 NR
Signiﬁcant incidental ﬁndings 108 6.1% 28 6.0% 80 6.2% 0.1 10.2%
Note: NLST ¼ National Lung Screening Trial; NCCN ¼ National Comprehensive Cancer Network; NR ¼ not reported.Four hundred thirty-two of 1,760 screened individuals
(28%) were patients from outside our institution, for whom
clinical follow-up after the prevalence CT lung screening
examinations was not available during this retrospective re-
view. For the remaining 1,328 patients, overall average
clinical follow-up after the prevalence examination was 12.5
months: 12.1  6.5 months (range, 2.1e25.5 months) in
group 2 and 12.7  6.5 months (range, 2.1e25.7 months)
in group 1 (Table 1).
Twenty-three of 1,328 screened patients (1.6%) with
clinical follow-up were diagnosed with at least one lungTable 3. Lung cancer diagnoses
Group Case
Stage
T N M Ov
1 C T1a N0 M0 I
1 P T1a N0 M0 I
1 D T1a N0 M0 I
1 H T1a N0 M0 I
1 F T1a N0 M0 I
1 O T1a N0 M0 I
1 G T1b N0 M0 I
1 I T1b N0 M0 I
1 E T1 N0 M0 I
1 K T2a N0 M0
1 J T1b N1 M0 I
1 B T1a N1 M0 I
1 Q T1a N2 M0 II
1 M T1a N2 M0 II
1 L T2a N2 M0 II
1 A T3 N1 M1a I
1 N T2a N1 M1b I
2 D T1a N0 M0 I
2 C T1a N0 M0 I
2 A T1a N0 M0 I
2 F T1a N0 M0 I
2 B T3 N0 M0 I
2 E T2a N0 M1b I
Note: AWD ¼ alive with disease; DOC ¼ died of other cause; DOD¼ died of
non-small-cell lung cancer.
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group 1. The overall annualized rate of malignancy detec-
tion was 1.6%: 1.8% in group 2 and 1.6% in group 1.
Overall average time from prevalence examination to cancer
diagnosis was 4.1 months: 5.6 months in group 2 and 3.7
months in group 1. Eleven of 23 patients (48%) had
adenocarcinoma, 5 (22%) had squamous cell carcinoma, 2
(9%) had small cell carcinoma, 1 (4%) had a carcinoid, and
1 (4%) had 3 synchronous small primary lung cancers,
squamous cell carcinoma, adenocarcinoma, and adenosqu-
amous carcinoma. Three patients (13%) deemed unable toGrade Histology Statuserall
A NA Squamous NED
A NA Presumed NSCLC NED
A 2/4 Adenocarcinoma NED
A NA Squamous NED
A NA Presumed NSCLC NED
A 3/4 Adenocarcinoma DOC
A 1/4 Adenocarcinoma NED
A 1/4 Carcinoid NED
A 2/4 Squamous NED
Adenocarcinoma
Adenosquamous
IB 3/4 Squamous NED
IA 3/4 Adenocarcinoma NED
IA 2/4 Squamous AWD
IA NA Adenocarcinoma AWD
IA NA Small cell carcinoma AWD
IA NA Adenocarcinoma AWD
V NA Adenocarcinoma AWD
V NA Small cell carcinoma AWD
A 1/4 Adenocarcinoma NED
A NA Presumed NSCLC NED
A 2/4 Adenocarcinoma NED
A 3/4 Adenocarcinoma NED
IB NA Squamous DOD
V NA Adenocarcinoma AWD
disease; NA ¼ not applicable; NED ¼ no evidence of disease; NSCLC ¼
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Table 4. Malignancy rate and average follow-up
Variable Overall Group 2 Group 1
Overall malignancy rate 23/1,328 (1.7%) 6/331 (1.8%) 17/997 (1.7%)
Average follow-up (mo) 12.5 12.1 12.7
Annualized malignancy rate 1.6% 1.8% 1.6%
Time to diagnosis (mo) 4.1 5.6 3.7
Average follow-up from diagnosis (mo) 7.8 5.3 8.6tolerate biopsy were diagnosed with stage I lung cancer on
the basis of PET positivity, suspicious growth rate, and
multidisciplinary consensus and were subsequently treated
with stereotactic body radiotherapy. Fourteen of 23 cancer
patients (61%) were in stage I, 4 (17%) were in stage II, 2
(9%) were in stage III, and 3 (13%) were in stage IV at time
of diagnosis. Twenty-one of 23 patients (91%) with diag-
nosed lung cancer were alive at the time of retrospective
review. Of those alive, 14 (61%) had no evidence of disease.
Average overall follow-up was 7.8 months from diagnosis:
5.3 months in group 2 and 8.6 months in group 1 (Tables 3
and 4).DISCUSSION
Twenty-six percent of participants in our high-risk clinical
CT lung screening program did not meet group 1 inclusion
criteria and qualiﬁed for screening through group 2
(Table 1, Fig. 2). Applied nationwide, a group 2 rate of 26%
would equate to approximately 2 million Americans at high
risk for lung cancer outside the entry criteria of the NLST
[6]. Additionally, as nearly one-third of our group 2 pop-
ulation failed to meet group 1 criteria solely because they
quit smoking >15 years previously, 600,000 former
smokers between 55 and 74 of age with >30-pack-year
smoking histories could lose access to screening with na-
tional eligibility limited to group 1.
Enrolling group 2 individuals does require additional
provider and insurer infrastructure to assess risk factors
beyond age and smoking history. To efﬁciently manage
intake resources required in our clinical CT lung screening
program, once a candidate was found to have a qualifying
risk factor for group 2, the presence of additional risk factors
was not formally assessed. As such, it is possible that the
order in which risk factors were assessed during the enroll-
ment process may have inﬂuenced the breakdown of qual-
ifying risk factors in our group 2 population. Future research
is needed to comprehensively address the presence of addi-
tional risk factors in this group.
To be considered for screening, patients were required
to be asymptomatic and were instructed in writing and
verbally at multiple points to forgo screening for 12 weeks
after clinical symptoms of pulmonary infection had resolved.196Despite these focused efforts, 6.5% of patients had radio-
graphic evidence of evolving or resolving infection on their
screening examinations, with similar frequencies in groups 1
and 2. Our rate of clinically signiﬁcant incidental ﬁndings
was also nearly identical for group 1 and group 2 at
approximately 6.0% and was signiﬁcantly less than the
10.2% reported on the prevalence screen in the NLST [6].
This difference may be explained by the fact that approxi-
mately 20% of our screened patients had prior cross-
sectional imaging of at least part of the chest available for
review at time of examination interpretation or that some
cases of suspected infection were included in this category in
the NLST.
The overall average age and smoking history of group 2
in our study cohort were slightly lower than those of group
1, with a more notable difference in duration of smoking
cessation among former smokers in each group (18.5 years
in group 2 vs 6.7 years in group 1) (Table 1). Despite these
statistically signiﬁcant differences in age, smoking history,
and smoking cessation characteristics, there was no statisti-
cally signiﬁcant difference in the rate of positive results be-
tween group 2 and group 1, and the positive rates are similar
to those reported on the prevalence screen in the NLST
[11]. As reported in the NLST, the percentage of early-stage
(stages I and II) lung cancers detected was approximately
75%, with subgroup analysis of histology and stage between
group 1 and group 2 limited because of the small overall
number of cancers detected. Similar CT lung screening
positive rates and malignancy detection rates between group
2 and group 1 (NLST population) offer the potential to save
thousands of additional lives every year by expanding CT
lung screening eligibility to include group 2 high-risk in-
dividuals [13].TAKE-HOME POINTSn We found no statistically signiﬁcant difference in the
rate of positive results between NCCN group 2 and
group 1 (NLST population), with overall positive re-
sults equivalent to those reported in the prevalence
screen of the NLST.Journal of the American College of Radiology
Volume 12 n Number 2 n February 2015
n The annualized cancer detection rates for NCCN
group 2 and group 1 were nearly identical at 1.8% and
1.6%, respectively.
n Expanding CT lung screening eligibility to include
NCCN group 2 could increase the number of quali-
ﬁed Americans by 2 million, including 600,000 who
would otherwise meet the NLST entry criteria except
for the fact that they quit smoking >15 years ago.
n Providing NCCN group 2 with access to CT lung
screening offers the potential to save thousands of
additional lives each year.REFERENCES
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